How long do semaglutide side effects last depends primarily on the dose escalation schedule rather than individual injection days, with clinical trials showing individual nausea episodes lasting a median of 8 days while overall digestive complaints cluster during the multi-week escalation window.
At Longevity Benchmark, every guide we write starts from the primary source, so the timings below come from the prescribing information and the published trial papers.
The Verdict
Why the Half-Life Sets the Timing
Semaglutide has an elimination half-life of approximately 1 week, which means circulating drug concentrations change gradually over weeks rather than dropping sharply between weekly injections. Following subcutaneous administration, the absolute bioavailability of semaglutide is 89%, and maximum concentration is reached 1 to 3 days post dose. Similar exposure occurs whether injected in the abdomen, thigh, or upper arm.
Because of this clearance rate, the Wegovy prescribing information states that semaglutide will be present in the circulation for about 5 to 7 weeks after the last injectable dose of 2.4 mg or oral dose of 25 mg. The Ozempic prescribing information states that semaglutide remains in the blood for about 5 weeks after the last dose.
The Ozempic label states that steady-state exposure is achieved after 4 to 5 weeks of once-weekly administration. The Wegovy label read for this page does not print a time-to-steady-state figure, so the same interval should not be assumed for Wegovy 2.4 mg. Because exposure accumulates across consecutive doses, adverse reactions track the multi-week dose step rather than the day of the injection.
Label Dose Escalation Schedules
Both injectable labels print a stepped, multi-week escalation and say why: to reduce the risk of gastrointestinal adverse reactions. Patients do not start on full maintenance doses. Both begin at 0.25 mg once weekly. The Wegovy label then prints fixed four-week windows; the Ozempic label sets a minimum of four weeks on each dose before the next increase, with no calendar attached.
What the Wegovy label prints (Table 1). This is the label's schedule, not advice.
| Wegovy Escalation Window | Weekly Dosage | Label Classification |
|---|---|---|
| Weeks 1 through 4 | 0.25 mg once weekly | Starting dosage |
| Weeks 5 through 8 | 0.5 mg once weekly | Dose escalation step |
| Weeks 9 through 12 | 1.0 mg once weekly | Dose escalation step |
| Weeks 13 through 16 | 1.7 mg once weekly | Dose escalation step |
| Week 17 and onward | 1.7 mg or 2.4 mg once weekly | Indication-specific maintenance dosage |
Prescribing Differences Between Wegovy and Ozempic
The Wegovy label sets the maintenance dosage for weight reduction in adults and adolescents aged 12 and older at either 2.4 mg or 1.7 mg once weekly. Prescribers are instructed to consider treatment response and tolerability when selecting the maintenance dosage. For noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), the maintenance dosage is 2.4 mg once weekly.
What the Ozempic label prints. This is the label's schedule, not advice.
| Ozempic Titration Stage | Dosage | Prescribing Direction |
|---|---|---|
| Starting dosage | 0.25 mg once weekly for 4 weeks | Initiated to reduce gastrointestinal adverse reactions |
| After 4 weeks on 0.25 mg | Increase to 0.5 mg once weekly | Initial maintenance or interim escalation step |
| After at least 4 weeks on 0.5 mg | May increase to 1.0 mg once weekly | Additional glycemic control step if needed |
| After at least 4 weeks on 1.0 mg | May increase to 2.0 mg once weekly | Maximum recommended dosage is 2.0 mg once weekly |
Onset and Clustering During Escalation Steps
The labels do not print an onset interval for gastrointestinal symptoms. What they do report is where the events cluster: the Wegovy label states that gastrointestinal reactions "were most frequently reported during dosage escalation", and the Ozempic and Rybelsus labels state that "the majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation". Semaglutide reaches maximum concentration 1 to 3 days after a subcutaneous dose, so exposure builds over days rather than hours.
Injectable semaglutide is administered once weekly on the same day each week, at any time of day, with or without meals. The time of day and the injection site can be changed without dosage modifications. The Ozempic label notes that the day of weekly administration can be changed if the time between two doses is at least 2 days.
The exact biological mechanism driving nausea during escalation remains unsettled. In a pooled analysis of the STEP clinical trials published by Wharton and colleagues, the authors noted that a 12-week study of semaglutide 1.0 mg using a paracetamol absorption test showed a delay in first-hour gastric emptying after a meal. However, a 20-week study of semaglutide 2.4 mg did not identify such a delay. The authors observed that the physiological cause of nausea remains uncertain and may involve central brain mechanisms rather than isolated gastric slowing.
Median Episode Lengths in the Trials
Clinical trial analyses show that individual episodes of digestive upset generally resolve within days rather than persisting indefinitely. In the pooled STEP 1 to 3 analysis evaluating once-weekly semaglutide 2.4 mg, Kaplan-Meier estimates identified distinct median durations for individual events.
The median duration of an individual episode of nausea was 8 days in the semaglutide 2.4 mg group. Individual bouts of diarrhoea lasted a median of 3 days, while vomiting episodes resolved in a median of 2 days. The study authors noted that these recovery intervals were similar to those observed in the placebo group.
Constipation ran longer than the others in the trials. The median episode was 47 days on semaglutide 2.4 mg against 35 days on placebo, and its prevalence plateaued at about week 10. While acute nausea and loose stools occurred in discrete episodes, constipation presented as a longer-lasting complaint.
What the Trials Actually Timed
Trial measurements demonstrate how adverse events evolve as patients transition from initial escalation into long-term maintenance. In the pooled STEP 1 to 3 analysis, gastrointestinal adverse events were reported most frequently within the dose-escalation period. The cumulative incidence of participants experiencing their first gastrointestinal adverse event plateaued after week 20.
The prevalence of nausea, diarrhoea, and vomiting in the semaglutide 2.4 mg group peaked at about week 20 and decreased thereafter, with the most prominent decline found for nausea. In the randomized withdrawal trial STEP 4 published by Rubino and colleagues, participants completed a 20-week run-in to 2.4 mg before randomization. After week 20 there were only two discontinuations because of gastrointestinal adverse events across the whole randomised period.
What the trials actually timed in the semaglutide 2.4 mg arm (pooled STEP 1 to 3 and STEP 4). This reflects clinical trial findings, not individual patient guarantees.
| Clinical Trial Parameter | Observed Trial Timing and Incidence |
|---|---|
| First gastrointestinal adverse event cumulative incidence | Plateaued after week 20 in pooled STEP 1 to 3 |
| Nausea, diarrhoea, and vomiting prevalence | Peaked at about week 20 and decreased thereafter |
| Constipation prevalence | Plateaued at approximately week 10 with 47-day median episode duration |
| Dose reduction or temporary treatment interruption | Occurred in 12.5% on semaglutide 2.4 mg versus 1.7% on placebo |
| Permanent discontinuation due to digestive symptoms | 4.3% on semaglutide 2.4 mg versus 0.7% on placebo, mostly during escalation |
| Discontinuations for digestive events after week 20 | Two discontinuations across the entire randomised period in STEP 4 |
Mitigations the Trial Authors Proposed
In the discussion of the pooled STEP 1 to 3 analysis, the authors list three mitigation approaches: counselling on meal size and stopping eating when feeling full, gradual dose escalation, and dose adjustment with re-escalation once the event resolved. They list them as proposals. None was tested as an intervention in these trials.
What to eat on a GLP-1 is covered in our guide to nutrient-dense foods on GLP-1.
The Wegovy label prints one sentence on escalation tolerability: "If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks." That sentence is addressed to the prescriber, and whether to extend a step is the prescriber's decision, not something to act on alone. If a dose step is not tolerable, that is the conversation to have at the next appointment or sooner.
For noncirrhotic MASH, the Wegovy label states that if patients do not tolerate 2.4 mg once weekly "the dosage can be decreased to 1.7 mg once weekly" and adds "Consider reescalation to 2.4 mg once weekly". On restarting after a gap, the Wegovy label states that if 2 or more consecutive doses are missed, dosing is resumed as scheduled or, if needed, Wegovy injection is reinitiated following the dosage escalation schedule, which the label says may reduce the gastrointestinal adverse reactions associated with reinitiation. That is a prescriber's call, and a missed run of doses is a reason to contact them rather than to restart on your own.
Clinical Warning Signs Requiring Prompt Prescriber Contact
Severe abdominal complaints or persistent vomiting represent clinical risks that require evaluation by a physician rather than passive waiting. The Wegovy prescribing information directs prescribers to monitor renal function in patients reporting adverse reactions that could lead to volume depletion, particularly during dosage initiation and escalation. Acute kidney injury occurred more frequently during dose titration in clinical studies.
Cardiovascular monitoring represents another labelled clinical boundary. The Wegovy label instructs prescribers to monitor heart rate at regular intervals consistent with usual clinical practice. Patients must report palpitations or a racing heartbeat at rest, and prescribers are instructed to discontinue therapy if patients experience a sustained increase in resting heart rate.
Concomitant medications also require clinical oversight. In patients with type 2 diabetes, blood glucose should be monitored before starting and during treatment. When initiating semaglutide, prescribers may consider reducing doses of concomitant insulin or insulin secretagogues to lower hypoglycaemia risk. If Ozempic and insulin are co-administered, the label directs that they must be given as separate injections that are not adjacent.
What Happens After Stopping: Drug Clearance and Weight Regain
Because of semaglutide's approximate 1-week elimination half-life, the medication clears slowly from systemic circulation. The Wegovy label states that semaglutide is present in the circulation for about 5 to 7 weeks after the last 2.4 mg injection or 25 mg oral dose. The Ozempic label states that the drug remains detectable in circulation for about 5 weeks after cessation.
Clinical trials did not track daily gastrointestinal recovery times following voluntary discontinuation, so there is no trial data on whether existing symptoms resolve immediately. What STEP 4 does show is that after week 20, new gastrointestinal events occurred less often in patients switched to placebo (26.1%) than in those continuing semaglutide 2.4 mg (41.9%). Discontinuations due to adverse events during that randomized phase were 2.4% in the semaglutide arm and 2.2% on placebo.
Stopping treatment leads to substantial weight regain in clinical trial extensions. In the STEP 1 trial extension published by Wilding and colleagues, participants lost a mean of 17.3% of body weight with semaglutide 2.4 mg over 68 weeks. One year after withdrawing both the drug and lifestyle intervention, participants regained 11.6 percentage points of lost weight by week 120, leaving them 5.6% below baseline. Cardiometabolic improvements in blood pressure, lipids, and HbA1c reverted towards baseline.
Withdrawal timing also governs reproductive planning. Because semaglutide remains in systemic circulation for weeks, the Wegovy label directs patients to discontinue the drug at least 2 months before a planned pregnancy. Perioperative timing, and how the 2023 and 2024 guidance differ, is covered in our semaglutide side effects guide.
Oral Semaglutide Absorption and Titration Differences
Oral semaglutide tablets exhibit a markedly different pharmacokinetic absorption profile compared with once-weekly subcutaneous injections. The absolute bioavailability of oral semaglutide tablets is approximately 1% to 2%, compared with 89% for subcutaneous injections. Maximum systemic concentration is reached roughly 1 hour after ingestion, compared with 1 to 3 days for injectable dosing.
For Wegovy tablets, the label establishes a 30-day escalation schedule: days 1 through 30 at 1.5 mg once daily, days 31 through 60 at 4 mg, days 61 through 90 at 9 mg, and day 91 onward at the 25 mg maintenance dosage. For the tablets, the Wegovy label states that if patients do not tolerate a dose during escalation, prescribers should consider delaying it, and that if the 25 mg once-daily maintenance dosage is not tolerated, they should consider switching to Wegovy injection 1.7 mg once weekly.
The oral formulation Rybelsus is supplied in two non-interchangeable formulations that cannot be substituted on a milligram-for-milligram basis. Formulation R1 steps through 3 mg, 7 mg, and 14 mg. The Rybelsus prescribing information states that the starting dosage of 3 mg once daily is not effective for glycemic control. Formulation R2 steps through 1.5 mg, 4 mg, and 9 mg daily.
Both oral tablets require strict administration logistics to ensure systemic absorption. Patients must take tablets upon waking on an empty stomach with up to 4 ounces of plain water, swallowing them whole without chewing or crushing. Patients must wait at least 30 minutes before eating, drinking, or taking other oral medications. If you want to know how the timing works for you, note when symptoms start relative to your last injection and take that to your prescriber, who decides what happens to the dose.
Frequently Asked Questions
How long do semaglutide side effects last?
How long semaglutide side effects last depends on whether you measure an individual symptom episode or the overall escalation window. In the pooled STEP 1 to 3 clinical trials testing semaglutide 2.4 mg, Kaplan-Meier estimated median durations of individual episodes were 8 days for nausea, 3 days for diarrhoea, and 2 days for vomiting, which were similar to placebo durations. Constipation ran longer, with a median episode duration of 47 days. Across the broader treatment timeline, new gastrointestinal adverse events occurred primarily during the multi-week dose-escalation phase. First-event cumulative incidence plateaued after week 20, and symptom prevalence declined after the 2.4 mg maintenance dose was reached.
When do semaglutide side effects start?
The prescribing information for Wegovy, Ozempic, and Rybelsus does not print a specific symptom-onset clock following an individual dose. What the regulatory labels do document is that gastrointestinal reactions cluster primarily during dosage escalation rather than during stable maintenance therapy. Pharmacokinetically, subcutaneous semaglutide reaches maximum blood concentrations 1 to 3 days post dose. Exposure accumulates over several weeks, with the Ozempic label noting that steady-state blood concentrations require 4 to 5 weeks of once-weekly administration. Digestive complaints therefore emerge most prominently across the 4-week dose increments rather than arriving immediately in the hours after an injection.
When do semaglutide side effects peak?
In clinical trials evaluating once-weekly semaglutide 2.4 mg, gastrointestinal side effects peaked near week 20 of treatment. A pooled analysis of the STEP 1 to 3 trials demonstrated that the prevalence of nausea, diarrhoea, and vomiting reached its maximum at approximately week 20 and decreased steadily thereafter. The decline was most prominent for nausea. In the same pooled trial analysis, the cumulative incidence of participants reporting their first gastrointestinal adverse event plateaued after week 20. Constipation followed a slightly earlier trajectory, with prevalence plateauing at approximately week 10 before persisting as a chronic background complaint.
Do semaglutide side effects go away?
Clinical trial evidence shows that most digestive adverse events are transient and decline significantly once patients reach a stable maintenance dose. The authors of the pooled STEP 1 to 3 analysis concluded that gastrointestinal adverse events typically resolve within a few days per episode, although a small proportion of patients continue to report symptoms throughout treatment. In the randomized withdrawal trial STEP 4, participants completed a 20-week escalation run-in to 2.4 mg. After week 20 there were only two discontinuations because of gastrointestinal adverse events across the whole randomised period, confirming that treatment intolerance drops sharply once escalation concludes.
Why do side effects come back when the dose increases?
Side effects cluster around dose increases in the trials, but the underlying biological reason is not fully settled. The prescribing information states that semaglutide delays gastric emptying, which can contribute to digestive upset. However, the pooled STEP analysis reports that while a 12-week study of semaglutide 1.0 mg found a first-hour gastric emptying delay on a paracetamol absorption test, a 20-week study of 2.4 mg found no such delay. The authors concluded that the mechanism of GLP-1 nausea remains uncertain and may involve central brain signaling. What the trials clearly show is that gastrointestinal reactions occur predominantly during dose escalation.
What helps with semaglutide nausea?
The authors of the pooled STEP clinical trial analysis identified three practical mitigations used within trial protocols: patient education on reducing meal size and stopping eating when full, gradual dose escalation, and dose adjustments with re-escalation once symptoms resolve. The Wegovy label explicitly instructs prescribers that if a patient does not tolerate a dosage step during titration, they should consider delaying dose escalation for 4 weeks. Any modification to a titration schedule, temporary dose reduction, or use of anti-emetic therapy must be directed by the prescribing clinician rather than initiated independently by the patient.
What happens when you stop semaglutide?
When you stop semaglutide, the drug clears over about 5 to 7 weeks after a Wegovy 2.4 mg injection, and about 5 weeks after Ozempic. No trial read for this page tracked whether existing digestive symptoms resolve after stopping, so there is no figure to give. What STEP 4 does show is that new gastrointestinal events were reported less often on placebo (26.1%) than on continued semaglutide 2.4 mg (41.9%). In the STEP 1 trial extension, participants who discontinued semaglutide 2.4 mg and lifestyle interventions regained 11.6 percentage points of their lost weight by week 120, while blood pressure, blood lipids, and blood sugar reverted toward baseline.
Do semaglutide side effects start immediately after the injection?
Semaglutide side effects do not typically start immediately in the minutes or hours following an injection. Subcutaneous semaglutide has an absolute bioavailability of 89% and reaches maximum circulating concentrations 1 to 3 days post dose. Because the medication is absorbed gradually and has an elimination half-life of approximately 1 week, drug exposure accumulates slowly. Prescribing information for Wegovy and Ozempic states that the majority of nausea, vomiting, and diarrhoea reports cluster during multi-week dose-escalation periods rather than immediately following an individual shot.